PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26137992-0 2015 Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. darolutamide 13-20 androgen receptor Homo sapiens 39-56 26137992-5 2015 ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR. darolutamide 0-7 androgen receptor Homo sapiens 36-38 26137992-5 2015 ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR. darolutamide 0-7 androgen receptor Homo sapiens 116-118 26137992-9 2015 In conclusion, ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs. darolutamide 15-22 androgen receptor Homo sapiens 35-37 26137992-9 2015 In conclusion, ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs. darolutamide 15-22 androgen receptor Homo sapiens 77-79 33237495-1 2020 Oral darolutamide (Nubeqa ) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). darolutamide 5-17 androgen receptor Homo sapiens 82-99 26313416-6 2015 The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. darolutamide 28-35 androgen receptor Homo sapiens 54-56 24974051-1 2014 BACKGROUND: ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. darolutamide 12-19 androgen receptor Homo sapiens 31-48 24974051-1 2014 BACKGROUND: ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. darolutamide 12-19 androgen receptor Homo sapiens 50-52 24974051-1 2014 BACKGROUND: ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. darolutamide 12-19 androgen receptor Homo sapiens 155-157 24974051-1 2014 BACKGROUND: ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. darolutamide 12-19 androgen receptor Homo sapiens 155-157 33237495-1 2020 Oral darolutamide (Nubeqa ) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). darolutamide 5-17 androgen receptor Homo sapiens 101-103 33237495-1 2020 Oral darolutamide (Nubeqa ) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). darolutamide 19-25 androgen receptor Homo sapiens 82-99 33237495-1 2020 Oral darolutamide (Nubeqa ) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). darolutamide 19-25 androgen receptor Homo sapiens 101-103 34449248-2 2022 Androgens and the androgen receptor (AR) play a critical role in prostate carcinogenesis, and targeting the AR signaling axis with abiraterone, enzalutamide, darolutamide, and apalutamide has improved outcomes for men with this lethal disease. darolutamide 158-170 androgen receptor Homo sapiens 18-35 34449248-2 2022 Androgens and the androgen receptor (AR) play a critical role in prostate carcinogenesis, and targeting the AR signaling axis with abiraterone, enzalutamide, darolutamide, and apalutamide has improved outcomes for men with this lethal disease. darolutamide 158-170 androgen receptor Homo sapiens 108-110 34449248-2 2022 Androgens and the androgen receptor (AR) play a critical role in prostate carcinogenesis, and targeting the AR signaling axis with abiraterone, enzalutamide, darolutamide, and apalutamide has improved outcomes for men with this lethal disease. darolutamide 158-170 androgen receptor Homo sapiens 37-39 34362254-4 2021 The current data support the efficacy of three novel androgen receptor targeted agents (ARTA), darolutamide, apalutamide and enzalutamide. darolutamide 95-107 androgen receptor Homo sapiens 53-70 34526701-5 2021 The introduction of potent androgen receptor signalling inhibitors (ARSIs), such as abiraterone, apalutamide, enzalutamide and darolutamide, has led to a renewed interest in using neoadjuvant hormonal treatment in high-risk prostate cancer. darolutamide 127-139 androgen receptor Homo sapiens 27-44 34208290-0 2021 Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. darolutamide 14-26 androgen receptor Homo sapiens 50-67 34208290-4 2021 Unlike other AR antagonists, we demonstrate that darolutamide exhibits consistent efficiency against all characterized gain-of-function mutations in a full-length AR. darolutamide 49-61 androgen receptor Homo sapiens 163-165 34866168-0 2022 Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. darolutamide 61-73 androgen receptor Homo sapiens 33-50 34866168-1 2022 BACKGROUND: Darolutamide is a second-generation androgen receptor inhibitor approved for the treatment of nonmetastatic castration-resistant prostate cancer at a dosage of 600 mg orally twice daily. darolutamide 12-24 androgen receptor Homo sapiens 48-65 34866168-12 2022 CONCLUSIONS: Darolutamide 600 mg twice daily demonstrates predictable linear pharmacokinetics and sustainably high plasma concentrations, suggesting the potential for constant inhibition of the androgen receptor signaling pathway. darolutamide 13-25 androgen receptor Homo sapiens 194-211 34884545-2 2021 Agents such as abiraterone, enzalutamide, apalutamide, darolutamide were designed to further suppress androgen receptor signaling following gonadal suppression achieved by first-line androgen deprivation therapies. darolutamide 55-67 androgen receptor Homo sapiens 102-119 34128827-5 2021 Specifically, the CYP17 inhibitor abiraterone acetate and the 2nd generation AR antagonists (enzalutamide, apalutamide and darolutamide) achieved OS benefits for PC patients, confirmed the importance of reactivated AR signaling in castration-resistant PC and validated important concepts that had been proposed in the field several decades ago but had remained so far unproven, including adrenal-targeted therapy and combined androgen blockade. darolutamide 123-135 androgen receptor Homo sapiens 77-79 32958445-5 2021 The phase 3 PROSPER, SPARTAN, and ARAMIS trials for enzalutamide, apalutamide, and darolutamide, the 3 approved androgen receptor inhibitors for men with nmCRPC, were all associated with increased metastasis-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC). darolutamide 83-95 androgen receptor Homo sapiens 112-129 35579577-5 2022 The US Food and Drug Administration has approved 3 next-generation AR inhibitors for nonmetastatic CRPC: apalutamide, enzalutamide, and darolutamide. darolutamide 136-148 androgen receptor Homo sapiens 67-69 35390118-11 2022 Targeting the AR signaling pathway led to the development of second-generation AR antagonists, examples of which include enzalutamide, apalutamide, and darolutamide. darolutamide 152-164 androgen receptor Homo sapiens 14-16 35390118-11 2022 Targeting the AR signaling pathway led to the development of second-generation AR antagonists, examples of which include enzalutamide, apalutamide, and darolutamide. darolutamide 152-164 androgen receptor Homo sapiens 79-81 33785516-0 2021 Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans. darolutamide 82-94 androgen receptor Homo sapiens 54-71 33135506-2 2021 Apalutamide, enzalutamide, and most recently, darolutamide (novel androgen receptor antagonists) have been approved for nonmetastatic castration-resistant prostate cancer (nmCRPC). darolutamide 46-58 androgen receptor Homo sapiens 66-83 33140306-2 2021 Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) has altered the course of advanced PCa. darolutamide 119-131 androgen receptor Homo sapiens 20-37 35490582-0 2022 Development of novel androgen receptor antagonists based on the structure of darolutamide. darolutamide 77-89 androgen receptor Homo sapiens 21-38 35490582-2 2022 Darolutamide 4 (ODM-201) is a promising second- generation antiandrogen because of its unique chemical structure and good activity against androgen receptor (AR). darolutamide 16-23 androgen receptor Homo sapiens 139-156 35490582-2 2022 Darolutamide 4 (ODM-201) is a promising second- generation antiandrogen because of its unique chemical structure and good activity against androgen receptor (AR). darolutamide 16-23 androgen receptor Homo sapiens 158-160 35553247-2 2022 Recently, 3 phase III trials have shown that the addition of next-generation androgen-receptor inhibitors (ARIs) apalutamide, darolutamide, and enzalutamide to ADT allows patients with high-risk nmCRPC to delay the appearance of metastasis and to obtain long-term clinical benefits. darolutamide 126-138 androgen receptor Homo sapiens 77-94 35179323-1 2022 BACKGROUND: Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. darolutamide 12-24 androgen receptor Homo sapiens 37-54 35184345-0 2022 A case of skin rash during oral administration of a novel androgen receptor inhibitor, darolutamide. darolutamide 87-99 androgen receptor Homo sapiens 58-75 35201849-0 2022 A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. darolutamide 150-162 androgen receptor Homo sapiens 36-53 35343943-0 2022 Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man. darolutamide 79-91 androgen receptor Homo sapiens 105-122 32823970-6 2020 Finally, the developed approach was used to make predictions of AR mutant response to the latest AR inhibitor darolutamide, which were then validated by in-vitro experiments. darolutamide 110-122 androgen receptor Homo sapiens 64-66 32333502-3 2020 Here, we studied in detail the global impact of darolutamide, a newly approved AR antagonist, on the transcriptome and AR-bound cistrome in two PCa cell models. darolutamide 48-60 androgen receptor Homo sapiens 79-81 32333502-3 2020 Here, we studied in detail the global impact of darolutamide, a newly approved AR antagonist, on the transcriptome and AR-bound cistrome in two PCa cell models. darolutamide 48-60 androgen receptor Homo sapiens 119-121 32333502-4 2020 Darolutamide strongly depleted the AR from gene regulatory regions and abolished AR-driven transcriptional signaling. darolutamide 0-12 androgen receptor Homo sapiens 35-37 32333502-4 2020 Darolutamide strongly depleted the AR from gene regulatory regions and abolished AR-driven transcriptional signaling. darolutamide 0-12 androgen receptor Homo sapiens 81-83 32333502-9 2020 Conversely, low FOXA1, BRD4 and H3K27ac levels were observed at regulatory sites that responded strongly to androgen stimulation, and AR interactions at these sites was blocked by darolutamide. darolutamide 180-192 androgen receptor Homo sapiens 134-136 32333502-13 2020 Our findings demonstrate that darolutamide is a potent AR antagonist blocking genome-wide AR enhancer and SE activation, and downstream transcription. darolutamide 30-42 androgen receptor Homo sapiens 55-57 32333502-13 2020 Our findings demonstrate that darolutamide is a potent AR antagonist blocking genome-wide AR enhancer and SE activation, and downstream transcription. darolutamide 30-42 androgen receptor Homo sapiens 90-92 32881669-0 2021 Darolutamide as a second-generation Androgen receptor inhibitor in the treatment of prostate cancer. darolutamide 0-12 androgen receptor Homo sapiens 36-53 32881669-4 2021 Darolutamide (ODM-201) is a second-generation androgen receptor (AR) inhibitor with a new chemical structure and has a high affinity to the AR. darolutamide 0-12 androgen receptor Homo sapiens 46-63 32881669-4 2021 Darolutamide (ODM-201) is a second-generation androgen receptor (AR) inhibitor with a new chemical structure and has a high affinity to the AR. darolutamide 0-12 androgen receptor Homo sapiens 65-67 32881669-4 2021 Darolutamide (ODM-201) is a second-generation androgen receptor (AR) inhibitor with a new chemical structure and has a high affinity to the AR. darolutamide 0-12 androgen receptor Homo sapiens 140-142 32881669-4 2021 Darolutamide (ODM-201) is a second-generation androgen receptor (AR) inhibitor with a new chemical structure and has a high affinity to the AR. darolutamide 14-21 androgen receptor Homo sapiens 46-63 32881669-4 2021 Darolutamide (ODM-201) is a second-generation androgen receptor (AR) inhibitor with a new chemical structure and has a high affinity to the AR. darolutamide 14-21 androgen receptor Homo sapiens 65-67 32881669-4 2021 Darolutamide (ODM-201) is a second-generation androgen receptor (AR) inhibitor with a new chemical structure and has a high affinity to the AR. darolutamide 14-21 androgen receptor Homo sapiens 140-142 32881669-6 2021 Darolutamide also can inhibit the transcriptional activity of several AR mutant variants (F877L, F877L/T878A, and H875Y/T878A) which are Enzalutamide resistant. darolutamide 0-12 androgen receptor Homo sapiens 70-72 32881669-9 2021 Darolutamide has shown high potential in inhibiting the growth of MR49F (Enzalutamide resistant PC cells) and VCaP (Castration-resistant PC cells) cell lines and transcriptional activities of AR. darolutamide 0-12 androgen receptor Homo sapiens 192-194 32823970-6 2020 Finally, the developed approach was used to make predictions of AR mutant response to the latest AR inhibitor darolutamide, which were then validated by in-vitro experiments. darolutamide 110-122 androgen receptor Homo sapiens 97-99 32549073-10 2020 In metastatic as well as castration resistant PCa stages, adding androgen receptor targeted agents (abiraterone, apalutamide, darolutamide or enzalutamide) to androgen-deprivation therapy (ADT) could be considered in high risk patients. darolutamide 126-138 androgen receptor Homo sapiens 65-82 32562083-0 2020 Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells. darolutamide 116-128 androgen receptor Homo sapiens 69-86 32765070-7 2020 Among third-generation ARIs, darolutamide is unique in that it incorporates two pharmacologically active diastereomers and has demonstrated resistance to all known androgen receptor (AR) mutations. darolutamide 29-41 androgen receptor Homo sapiens 164-181 32765070-7 2020 Among third-generation ARIs, darolutamide is unique in that it incorporates two pharmacologically active diastereomers and has demonstrated resistance to all known androgen receptor (AR) mutations. darolutamide 29-41 androgen receptor Homo sapiens 23-25 31844181-11 2020 The AR antagonist darolutamide demonstrated a comparable incidence of cognitive disorder in clinical trials to that of ADT alone. darolutamide 18-30 androgen receptor Homo sapiens 4-6 31571146-1 2019 BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). darolutamide 27-39 androgen receptor Homo sapiens 51-68 32456317-6 2020 This has been further verified by the recent FDA approval of the other two second-generation AR antagonists, apalutamide and darolutamide, for the treatment of prostate cancer. darolutamide 125-137 androgen receptor Homo sapiens 93-95 31571146-1 2019 BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). darolutamide 27-39 androgen receptor Homo sapiens 70-72 32073798-1 2019 The results of a recent randomised phase 3 clinical trial show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate cancer, compared with placebo. darolutamide 101-113 androgen receptor Homo sapiens 72-89 31471641-0 2019 [A new androgen receptor antagonist : Darolutamide for patients with non-metastatic castration-resistant prostate cancer]. darolutamide 38-50 androgen receptor Homo sapiens 7-24 31437779-0 2019 Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. darolutamide 39-51 androgen receptor Homo sapiens 111-113 31437779-3 2019 Here, the structural modification of darolutamide resulted in the discovery of dual-action AR inhibitors and down-regulators. darolutamide 37-49 androgen receptor Homo sapiens 91-93 31605368-1 2019 Darolutamide (NUBEQA ) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer. darolutamide 0-12 androgen receptor Homo sapiens 64-81 31605368-1 2019 Darolutamide (NUBEQA ) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer. darolutamide 14-20 androgen receptor Homo sapiens 64-81 30828788-0 2019 Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. darolutamide 0-12 androgen receptor Homo sapiens 25-42 30828788-1 2019 Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. darolutamide 0-12 androgen receptor Homo sapiens 24-41 30828788-1 2019 Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. darolutamide 0-12 androgen receptor Homo sapiens 43-45 30828788-1 2019 Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. darolutamide 0-12 androgen receptor Homo sapiens 111-113 30828788-2 2019 Using cell-based transactivation assays, we demonstrate that darolutamide, its diastereomers and its main metabolite keto-darolutamide are strong, competitive antagonists for AR wild type, and also for several mutants identified in prostate cancer patients for which other AR antagonists show reduced antagonism or even agonism. darolutamide 61-73 androgen receptor Homo sapiens 175-177 30828788-2 2019 Using cell-based transactivation assays, we demonstrate that darolutamide, its diastereomers and its main metabolite keto-darolutamide are strong, competitive antagonists for AR wild type, and also for several mutants identified in prostate cancer patients for which other AR antagonists show reduced antagonism or even agonism. darolutamide 61-73 androgen receptor Homo sapiens 273-275 30828788-4 2019 Molecular modeling suggests that the flexibility of darolutamide allows accommodation in the W742C/L mutated AR ligand-binding pocket while for enzalutamide the loss of the important hydrophobic interaction with W742 leads to reduced AR interaction. darolutamide 52-64 androgen receptor Homo sapiens 109-111 30828788-4 2019 Molecular modeling suggests that the flexibility of darolutamide allows accommodation in the W742C/L mutated AR ligand-binding pocket while for enzalutamide the loss of the important hydrophobic interaction with W742 leads to reduced AR interaction. darolutamide 52-64 androgen receptor Homo sapiens 234-236 30115959-10 2019 The ARAMIS trial on darolutamide, another AR pathway inhibitor, is also ongoing, and can potentially be another fitting option for M0CRPC. darolutamide 20-32 androgen receptor Homo sapiens 4-6 30197098-0 2018 Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. darolutamide 24-36 androgen receptor Homo sapiens 46-63 30197098-6 2018 This review summarizes the key clinical data, including ongoing trials, for hormonal therapies in CRPC and provides an overview of the clinical development of darolutamide, a novel, nonsteroidal AR antagonist currently in phase III development for the treatment of nonmetastatic CRPC and metastatic hormone-sensitive PC. darolutamide 159-171 androgen receptor Homo sapiens 195-197 28851578-0 2018 Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). darolutamide 162-174 androgen receptor Homo sapiens 118-135 28851578-0 2018 Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). darolutamide 176-183 androgen receptor Homo sapiens 118-135 28851578-1 2018 Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. darolutamide 0-12 androgen receptor Homo sapiens 34-51 28851578-1 2018 Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. darolutamide 0-12 androgen receptor Homo sapiens 53-55 28851578-1 2018 Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. darolutamide 14-21 androgen receptor Homo sapiens 34-51 28851578-1 2018 Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. darolutamide 14-21 androgen receptor Homo sapiens 53-55 28851578-4 2018 Moreover, darolutamide inhibited the transcriptional activity of AR mutants identified in the plasma of CRPC patients progressing on traditional therapies. darolutamide 10-22 androgen receptor Homo sapiens 65-67 28851578-5 2018 In particular, darolutamide significantly inhibited the transcriptional activity of the F877L, H875Y/T878A, F877L/T878A, and the previously unreported T878G AR mutants, that transform enzalutamide into a partial agonist. darolutamide 15-27 androgen receptor Homo sapiens 157-159 28851578-6 2018 In silico cheminformatics computer modeling provided atomic level insights confirming darolutamide antagonist effect in F877L and T878G AR mutants. darolutamide 86-98 androgen receptor Homo sapiens 136-138 28490267-6 2017 Expert opinion: Darolutamide is an oral, investigational, high-affinity AR antagonist which has activity against known AR mutants that confer resistance to other second-generation antiandrogens, has minimal blood-brain barrier penetration, and does not significantly increase serum testosterone. darolutamide 16-28 androgen receptor Homo sapiens 72-74 28490267-6 2017 Expert opinion: Darolutamide is an oral, investigational, high-affinity AR antagonist which has activity against known AR mutants that confer resistance to other second-generation antiandrogens, has minimal blood-brain barrier penetration, and does not significantly increase serum testosterone. darolutamide 16-28 androgen receptor Homo sapiens 119-121 30824428-1 2019 The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. darolutamide 71-83 androgen receptor Homo sapiens 42-59 28851578-9 2018 We found that darolutamide delays growth of enzalutamide-resistant prostate cancer, in particular in cells with mutated forms of the androgen receptor after previous treatment. darolutamide 14-26 androgen receptor Homo sapiens 133-150